• Explore /
  • Poster
  • / Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.

Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.

Abstract Poster

Authors

null

Mehmet Altan

MD Anderson Cancer Center, Houston, TX

Mehmet Altan , Dawen Sui , Saumil Gandhi , Stephen Swisher , Natalie I Vokes , Mara Antonoff , Jianjun Zhang , George R. Blumenschein , Tina Cascone , Yasir Y Elamin , Carl Michael Gay , Don Lynn Gibbons , Xiuning Le , Marcelo Vailati Negrao , Ferdinandos Skoulidis , Anne S. Tsao , Janet Chen Tu , Amy R. Spelman , J. Jack Lee , John Heymach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03391869

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9049)

DOI

10.1200/JCO.2022.40.16_suppl.9049

Abstract #

9049

Poster Bd #

37

Abstract Disclosures

Similar Posters

First Author: Rohit K. Jain

First Author: Haeseong Park

First Author: Lorenzo Pilla

First Author: Talal El Zarif